A federal judge has ordered a research company to supply an experimental drug to a 16-year-old Minnesota boy who is terminally ill with muscular dystrophy.

A family says a drug company led them to believe that their 16-year-old son could participate in a clinical trial for an experimental muscular dystrophy drug, but then went back on its word.

It is a case that pits a mother desperately seeking a medical treatment for her son against a biotechnology company for whom she claims to have worked tirelessly as an advocate.